Loading
HKSEHealthcareMedical - Devices
Latest quote
HK$0.70
HK$0.00 · 0.00%
Austar Lifesciences Limited functions as an investment holding company, delivering integrated engineering and technology solutions to pharmaceutical production facilities and research institutions globally, with a significant presence in Mainland China. Its business activities are structured across six primary divisions: liquid and bioprocessing systems; controlled environment and automated monitoring systems; powder and solid material handling systems; Good Manufacturing Practice (GMP) adherence services; life science expendables; and the brokerage and supply of pharmaceutical machinery. The company's product portfolio is extensive, including systems for pharmaceutical water, liquid preparation, and bioprocessing; powder and solid processing units; clean utility infrastructure; and advanced cleanroom technology. They also supply automated control and monitoring systems, freeze-dryers, sterile filling equipment, and visual inspection apparatus. Furthermore, Austar provides products for pharmaceutical contamination control, aseptic packaging and containment, biosafety and lab animal equipment and consumables, single-use bioprocess components, and offers holistic laboratory setup solutions. Beyond its product offerings, Austar Lifesciences extends a wide array of professional services, such as design and engineering, quality risk management, expert consultation, research and development assistance, process optimization, and digitalization strategies. The company also offers post-sale support, on-site services, system upgrades, facility relocation guidance, and comprehensive asset management. Additionally, it serves as an agent and distributor for pharmaceutical equipment, providing associated assembly and pre-assembly services. Established in 1991, Austar Lifesciences Limited is headquartered in Shanghai, China.
Latest quote
HK$0.70
HK$0.00 · 0.00%
Regular session · HKT · Market data may be delayed.
Austar Lifesciences Limited functions as an investment holding company, delivering integrated engineering and technology solutions to pharmaceutical production facilities and research institutions globally, with a significant presence in Mainland China. Its business activities are structured across six primary divisions: liquid and bioprocessing systems; controlled environment and automated monitoring systems; powder and solid material handling systems; Good Manufacturing Practice (GMP) adherence services; life science expendables; and the brokerage and supply of pharmaceutical machinery. The company's product portfolio is extensive, including systems for pharmaceutical water, liquid preparation, and bioprocessing; powder and solid processing units; clean utility infrastructure; and advanced cleanroom technology. They also supply automated control and monitoring systems, freeze-dryers, sterile filling equipment, and visual inspection apparatus. Furthermore, Austar provides products for pharmaceutical contamination control, aseptic packaging and containment, biosafety and lab animal equipment and consumables, single-use bioprocess components, and offers holistic laboratory setup solutions. Beyond its product offerings, Austar Lifesciences extends a wide array of professional services, such as design and engineering, quality risk management, expert consultation, research and development assistance, process optimization, and digitalization strategies. The company also offers post-sale support, on-site services, system upgrades, facility relocation guidance, and comprehensive asset management. Additionally, it serves as an agent and distributor for pharmaceutical equipment, providing associated assembly and pre-assembly services. Established in 1991, Austar Lifesciences Limited is headquartered in Shanghai, China.
52-week range
Current HK$0.70
Regular session · HKT · Market data may be delayed.
Austar Lifesciences Limited functions as an investment holding company, delivering integrated engineering and technology solutions to pharmaceutical production facilities and research institutions globally, with a significant presence in Mainland China. Its business activities are structured across six primary divisions: liquid and bioprocessing systems; controlled environment and automated monitoring systems; powder and solid material handling systems; Good Manufacturing Practice (GMP) adherence services; life science expendables; and the brokerage and supply of pharmaceutical machinery. The company's product portfolio is extensive, including systems for pharmaceutical water, liquid preparation, and bioprocessing; powder and solid processing units; clean utility infrastructure; and advanced cleanroom technology. They also supply automated control and monitoring systems, freeze-dryers, sterile filling equipment, and visual inspection apparatus. Furthermore, Austar provides products for pharmaceutical contamination control, aseptic packaging and containment, biosafety and lab animal equipment and consumables, single-use bioprocess components, and offers holistic laboratory setup solutions. Beyond its product offerings, Austar Lifesciences extends a wide array of professional services, such as design and engineering, quality risk management, expert consultation, research and development assistance, process optimization, and digitalization strategies. The company also offers post-sale support, on-site services, system upgrades, facility relocation guidance, and comprehensive asset management. Additionally, it serves as an agent and distributor for pharmaceutical equipment, providing associated assembly and pre-assembly services. Established in 1991, Austar Lifesciences Limited is headquartered in Shanghai, China.
52-week range
Current HK$0.70
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (CNY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1.53B CNY | 1.5B CNY | 1.76B CNY | 2.16B CNY | 2.02B CNY |
| Cost of goods sold | 1.24B CNY | 1.2B CNY | 1.43B CNY | 1.77B CNY | 1.54B CNY |
| Gross profit | 293.27M CNY | 301.22M CNY | 336.05M CNY | 488.8M CNY | 479.01M CNY |
| Research and development | 45.07M CNY | 53.55M CNY | 55.33M CNY | 70.16M CNY | 65.6M CNY |
| Selling, general, and administrative | 224.99M CNY | 239.08M CNY | 300.99M CNY | 305.93M CNY | 298.38M CNY |
| Operating expenses | 239.12M CNY | 266.04M CNY | 366.04M CNY | 372.42M CNY | 167.09M CNY |
| Interest income | 1.42M CNY | 2.9M CNY | 3.11M CNY | 2.27M CNY | 1.47M CNY |
| Interest expense | 11.8M CNY | 17.2M CNY | 13.96M CNY | 9.59M CNY | 4.4M CNY |
| Depreciation and amortization | 29.95M CNY | 35.94M CNY | 45.6M CNY | 37.01M CNY | 13.65M CNY |
| Operating income | 54.15M CNY | 35.18M CNY | −29.99M CNY | 116.37M CNY | 311.92M CNY |
| Net income | 33.81M CNY | 16.08M CNY | −113.47M CNY | 87.46M CNY | 277.3M CNY |
Company facts updated Sep 6, 2026.
Recent quarterly results
Recent quarterly results
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | May 19, 2015 | HK$0.05Irregular | May 20, 2015 | Jun 26, 2015 |
Ex-dividend May 19, 2015
HK$0.05
Irregular
Record May 20, 2015 · Payment Jun 26, 2015
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
